Nuvox's stroke candidate could triple window of time compared to tPA
By Michael Fitzhugh
Tuesday, August 23, 2016
Chasing improved safety and decreased brain damage for stroke sufferers, Nuvox Pharma LLC is preparing for a fourth quarter start to a phase Ib study of NVX-208, one of multiple oxygen therapeutics the company is advancing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.